ClinicalTrials.gg
RecruitingNCT07382167Updated Jun 4, 2026

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

A Phase 3 interventional study of Tenapanor 5 mg BID and Tenapanor 25 mg BID in Chronic Idiopathic Constipation (CIC), sponsored by Ardelyx. Recruiting at 109 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Ardelyx · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
692
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.

Planned enrollment
Largest of 11
692 · median 186
Started
2026
the only one that year
Phase 3
7 of 11
2 open now
Registered
11th of 11
by date
Lead sponsor
9 of 11
Ardelyx

Among the 11 studies testing tenapanor in Constipation, this one has the largest planned enrollment, is the only one that started in 2026, is one of 7 in phase 3, and was the 11th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tenapanor in Constipation, or all of them as a file.
02

Study summary

This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.

Read the detailed description

This study consists of a 2-week Screening period, followed by a 26-week randomized treatment period (RTP), and a 4-week treatment-free Safety Follow-up period.

After obtaining study informed consent from patients, the 2-week Screening period starts. Patients will be fully assessed for eligibility into the study. The assessments will include evaluation of inclusion/exclusion criteria, including medical histories, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests.

Patients will also self-report, on information about the status of their constipation symptoms and severity via an electronic diary (eDiary). Patient compliance with the eDiary will be monitored to determine eligibility at the end of screening.

Eligible patients will be randomized (Visit 2) to receive tenapanor 5 mg BID (twice a day), 25 mg BID, 50 mg BID, or placebo for 26 consecutive weeks as the double-blind RTP. During this period, patients will continue recording daily assessments of constipation symptoms and weekly assessments of constipation severity in the eDiary. Patients will have return visits every two to six weeks at Weeks 2, 4, 8, 12, 16, 20 and 26(Visit 3-9) to undergo safety assessments.

Upon completion of the 26-week RTP, patients will be monitored for AEs (adverse events) during the 4-week treatment-free Safety Follow-up period and complete the Follow-up visit (Visit 10) at the end of this period to undergo safety assessments.

03

Conditions studied

  • Chronic Idiopathic Constipation (CIC)

Browse trials for

Keywords

  • CIC
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 to ≤80 years old at the Screening visit (Visit 1).
  2. Meet the Rome IV Diagnostic Criteria for functional constipation.
  3. Females of non-, or agree to the use of an acceptable means of for up to 30 days following the last dose of study medication.
  4. Males must agree to use an appropriate method of barrier contraception or have documented surgical sterilization.
  5. Meets the entry criteria assessed during the Screening period.
  6. Ability to understand and provide input on the assessments in the eDiary.
  7. Provide written before the initiation of any study-specific procedures.
  8. Must agree to have daily access to eDiary via a computer, tablet or smart phone

Exclusion criteria

Exclusion Criteria:

  1. Loose or watery stool in the absence of any medication that is known to affect stool consistency for >25% of bowel movements (BMs) during the 3 months prior to the Screening visit
  2. Fecal impaction within 6 months prior to the Screening visit
  3. Unexplained and alarm symptoms.
  4. Functional diarrhea as defined by Rome IV criteria
  5. IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome IV criteria
  6. Diagnosis or treatment of any clinically symptomatic abnormality of the GI tract or active disease within 6 months prior to the Screening visit
  7. Patient with central nervous system disorder
  8. Use of prohibited medications defined by protocol
  9. Patient has a history or current evidence of laxative abuse
  10. Hepatic dysfunction
  11. Positive , or test at screening
  12. Positive urinary drug test at Screening, with the exception of cannabis and cannabidiol (CBD)
  13. Any evidence of or treatment of within 1 year prior to the Screening visit
  14. Any surgery on the stomach, small intestine or colon; appendectomy or cholecystectomy are not excluded unless within 60 days prior to the Screening visit
  15. Pregnant women or women planning to become pregnant during trial participation
  16. A major psychiatric disorder that has required hospitalization in the last year prior to the Screening visit.
  17. Alcohol or substance abuse within 1 year prior to the Screening visit
  18. Participation in other clinical trials within 1 month prior to the Screening visit
  19. Clinical evidence of significant disease that may interfere with the patient's successful completion of the trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
692 participants (estimated)

Study arms

  • Experimental
    Tenapanor 5 mg BID

    Patients will be randomized to receive 5 mg tenapanor twice daily.

    Drug: Tenapanor 5 mg BID

  • Experimental
    Tenapanor 25 mg BID

    Patients will be randomized to receive 25 mg tenapanor twice daily.

    Drug: Tenapanor 25 mg BID

  • Experimental
    Tenapanor 50 mg BID

    Patients will be randomized to receive 50 mg tenapanor twice daily.

    Drug: Tenapanor 50 mg BID

  • Placebo comparator
    Placebo Comparator

    Patients will be randomized to receive matching placebo twice daily.

    Drug: Placebo

Interventions

  • Patients will receive tenapanor 5 mg BID (total of 10 mg daily)

  • Patients will receive tenapanor 25 mg BID (total of 50 mg daily)

  • Patients will receive tenapanor 50 mg BID (total of 100 mg daily)

  • DrugPlacebo

    Patients will receive matching placebo BID

06

What researchers measure

Primary outcomes

  1. Durable complete spontaneous bowel movements (CSBM) response

    Durable complete spontaneous bowel movements (CSBM) response is defined as achieving the weekly CSBM response for ≥9 out of the first 12 weeks of the randomized treatment period and and for ≥3 of the last 4 weeks of the first 12 weeks of randomized treatment period

    Time frame: 12 Weeks

Secondary outcomes

  1. 9/12 week complete spontaneous bowel movements (CSBM) response

    9/12 week complete spontaneous bowel movements (CSBM) response defined as achieving the weekly CSBM response for ≥9 out of the first 12 weeks of the randomized treatment period.

    Time frame: 12 Weeks

  2. Change from baseline in complete spontaneous bowel movements (CSBM) frequency

    Change from baseline over the first 12 weeks of the randomized treatment period in complete spontaneous bowel movements (CSBM) frequency

    Time frame: 12 Weeks

  3. Change from baseline in spontaneous bowel movement (SBM) frequency

    Change from baseline over the first 12 weeks of the randomized treatment period in spontaneous bowel movement (SBM) frequency

    Time frame: 12 Weeks

  4. Change from baseline in stool consistency

    Change from baseline over the first 12 weeks of the randomized treatment period in stool consistency

    Time frame: 12 Weeks

  5. Change from baseline in stool straining

    Change from baseline over the first 12 weeks of the randomized treatment period in straining

    Time frame: 12 Weeks

07

Study locations

109 of 109 sites recruiting

Showing the first 100 of 109 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2027, 13 months after the start.

Of 28 industry-sponsored phase 3 interventional studies under Constipation, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 13 months is below that.

Counting every sponsor, half of 36 studies reached it within 21 months; a quarter within 10 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 2, 2026
StartActual
Jan 13, 2026
Primary completionEst.
Feb 26, 2027
CompletionEst.
Jun 4, 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07382167
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Feb 2, 2026
Start date
Jan 13, 2026
Primary completion
Feb 26, 2027 (estimated)
Completion
Jun 4, 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Marica Tambongco
Contact
mtambongco@ardelyx.com
(617) 875-7968
Brian Quach
study director · Ardelyx Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion